Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 186 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Histologic evaluation Clear all
Completed Not applicable Interventional

EUS-FNB With ROSE Vs. EUS-FNB Without ROSE

NCT03322592
View directory record Official record
Conditions
Biopsy, Fine-needle, Pancreatic Neoplasm
Interventions
Rapid on-site evaluation (ROSE), Histologic evaluation
Diagnostic Test
Lead sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 23, 2026, 2:07 PM EDT
Terminated No phase listed Observational

A Registry Study Evaluating Outcomes in Breast Biopsy With the Intact™ Breast Lesion Excision System (BLES)

NCT03520127
View directory record Official record
Conditions
Breast Lesions
Interventions
Intact Breast Lesion Excision System (BLES)
Device
Lead sponsor
Medtronic Surgical Technologies
Industry
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • Atlanta, Georgia • Dalton, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 23, 2026, 2:07 PM EDT
Terminated Not applicable Interventional Results available

Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast

NCT01249157
View directory record Official record
Conditions
Breast Cancer
Interventions
Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Phase 1 Interventional

Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease

NCT05560607
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NASH
Interventions
AZD7503 Intervention
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 23, 2026, 2:07 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma

NCT01783535
View directory record Official record
Conditions
Retinoblastoma
Interventions
vincristine, topotecan, filgrastim, PEG-filgrastim, carboplatin, focal therapy, etoposide, cyclophosphamide, MESNA, doxorubicin, enucleation, external beam radiation or proton beam radiation
Drug · Other · Procedure + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Terminated Phase 4 Interventional Results available

Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy

NCT03333551
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
F18 Florbetapir (amyvid) cardiac PET/CT imaging
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Phase 1 Interventional

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

NCT04601402
View directory record Official record
Conditions
Solid Tumor, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
Interventions
GEN-001, Avelumab
Drug
Lead sponsor
Genome & Company
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
New Haven, Connecticut • Atlanta, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 23, 2026, 2:07 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

NCT04104776
View directory record Official record
Conditions
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions
Tulmimetostat, Enzalutamide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
22
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536
View directory record Official record
Conditions
Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Richter's Transformation, Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
Nemtabrutinib
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

NCT05013216
View directory record Official record
Conditions
High Risk Cancer, Pancreatic Cancer
Interventions
Cohort A: Patients at high risk of developing pancreatic cancer., Cohort B: Patients must have evidence of a pancreatic cystic neoplasm
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
40 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Not listed Phase 4 Interventional

Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)

NCT04149470
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Omeprazole 20mg BID
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 22 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 23, 2026, 2:07 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma

NCT00686842
View directory record Official record
Conditions
Kaposi's Sarcoma
Interventions
VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
La Jolla, California • Los Angeles, California • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Not applicable Interventional

Histological Analysis Following Ulthera System Treatment for Hyperhidrosis

NCT01708551
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Ulthera System Treatment
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 23, 2026, 2:07 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Morphological Markers of Gastroesophageal Reflux Disease (GERD)

NCT01921686
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease
Interventions
Sample collection and Questionnaire
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 18 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Phase 1 Interventional

First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

NCT03188965
View directory record Official record
Conditions
Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions
Elimusertib (BAY1895344)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
14
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Not applicable Interventional

Choline PET/CT and MRI for Targeted Prostate Biopsy

NCT01751737
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate Cancer Imaging
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 23, 2026, 2:07 PM EDT
Completed No phase listed Observational

Genetic Study of Young Patients With Colorectal Cancer

NCT00044967
View directory record Official record
Conditions
Colorectal Cancer
Interventions
microsatellite instability analysis
Genetic
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 49 Years
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
71
States / cities
Mobile, Alabama • Colton, California • Duarte, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 23, 2026, 2:07 PM EDT
Active, not recruiting Phase 2 Interventional

TheraSphere With Durvalumab and Tremelimumab for HCC

NCT05063565
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Phase 1Phase 2 Interventional

Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

NCT00553306
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
therapeutic autologous lymphocytes, aldesleukin, cyclophosphamide, biopsy, immunohistochemistry staining method, flow cytometry, polymerase chain reaction
Biological · Drug · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

NCT00499083
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Genetic + 3 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 23, 2026, 2:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions

NCT00633516
View directory record Official record
Conditions
Skin Cancer
Interventions
Optical Spectroscopy
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Irvine, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Not applicable Interventional Results available

FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy

NCT00125762
View directory record Official record
Conditions
Cirrhosis, Hepatitis B, Hepatitis C
Interventions
FibroScan
Device
Lead sponsor
Afdhal, Nezam, M.D.
Individual
Eligibility
18 Years to 90 Years
Enrollment
907 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 23, 2026, 2:07 PM EDT
Recruiting Not applicable Interventional

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors

NCT05313191
View directory record Official record
Conditions
CNS Cancer, Head and Neck Cancer, GI Cancer, Gynecologic Cancer, Prostate Cancer, Thoracic Cancer, Breast Cancer
Interventions
Pencil Beam Scanning Proton Therapy
Radiation
Lead sponsor
The New York Proton Center
Other
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Not listed No phase listed Observational

Scarring in Stratagraft-treated vs. Autograft-treated Burn Wounds: a Clinical and Histological Investigation

NCT04896346
View directory record Official record
Conditions
Burn Scar, Scar
Interventions
Punch biopsy, non-invasive photography, assessments, and measurements
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 23, 2026, 2:07 PM EDT